PB Fintech Q1 FY27 earnings call

What moved the numbers, as management explained it

• GI revenue NPV to compress to 33-40% of current once IRDA draft effective from 1 April 2027; life insurance NPV similar.
• Volume elasticity offset: 15-20% growth expected from price elasticity of ~1 if benefit passed to customer.
• Cost synergy opportunity of 10-15% of revenue from rationalizing digital marketing, brand spend, sales hiring, customer support.
• Hiring pace: 6,000 hires in H1 FY27 vs would have been ~2,000 had draft been known earlier; future hiring to slow as vintage improves productivity.
• Combined operating ratio framework continues: 70-80% of premium goes to claims, 16% paid to channel in some lines; quality-of-business and persistency improvements not currently rewarded. (accounting)

The numbers management led with

• General insurance commission revenue compression: GI revenue to fall to 'between one-third to 40% of what we have today' under the draft
• Total cost base: Roughly ₹3,000 crore total cost base across the business
• H1 FY27 hiring: ~6,000 people hired in H1 FY27; would have been ~2,000 under new economics
• Health combined operating ratio: 93% on health business with insurer partners

Guidance on this call

What changed since the Wed 5 Aug 2026 call

By business

Balance sheet, capex and funding

• Cost base of ~₹3,000 cr where rationalization levers exist; no specific debt, cash or capex figures cited on this call.
• Capital allocation to shift toward protecting core insurance distribution position; no fresh capital injection into loss-making new initiatives beyond meaningful support.

The industry, as management sees it

Management expects industry-wide recalibration of distribution economics, with smaller agents and brokers likely squeezed unless taken on-roll by insurers. They expect demand elasticity of ~1 to give some volume offset if pricing benefit flows to customers. Underlying view is that health insurance penetration (cited as <6 crore Indians) is gated by claims/service trust, not price.

Risks management named

• 30-40% revenue compression in general insurance if draft is implemented as-is
• Risk that benefit is not passed to customer, just transferred to insurer or distributor
• Renewal commission renegotiation with insurer partners could be contested
• POSP channel economics challenged under draft; viability uncertain
• Uncertainty on retrospective vs prospective application of new commission caps
• Implementation from 1 April leaves limited buffer to renegotiate economics

Not answered directly

• Retrospective vs prospective implementation of new commission caps
• Specific size of cost synergy (refused to commit a number beyond '10-15%')
• POSP viability post-IDE framework
• Industry consultation process with distributors

Asked for a number, answered without one

• Exact cost synergy number: Yashish hedged: 'there may be a 10-15%, let us say, current revenue-to-cost synergy possible' — said final numbers to come after a month or so of analysis.
• Whether the regulation is retrospective: Management declined: 'I can't answer that question... I don't have any clarity on whether it's retrospective or not' — too early (24 hours since paper).
• FY28 specific impact: Management hedged: 'FY28 year of challenges and discovery, maybe... hope is no impact on FY29. But FY27, no impact.'
• POSP model viability: Management said business 'is challenged' on top-line but 'may actually work in a different direction' on bottom-line; awaiting regulatory clarity.
• Manufacturing entry timeline and capital: Management said 'higher probability' but no timeline or capital committed; MGA may require one-third to half statutory capital but nothing concrete.

Every question, with its answer

1. 1. Call centre cost and product mix

   Manas Agrawal

   Question. Math from the regulator makes call centre cost structure difficult to sustain, especially in general insurance (health, motor). How are you thinking about product mix shifts strategically, and what does this mean for insurer market growth? Second, what cost synergies or optimisation strategies can you share to size the downside protection?

   Answer, Yashish Dahiya. Contact centre is ~20% of revenue; we run decile analysis where top 50% of salespeople deliver ~80% of sales. In a maintain-mode cost structure, we will rationalise the bottom deciles. Hiring will slow so vintage productivity improves. There are also revenue synergies between life and health businesses. Passed to Sarbvir to add operational detail.

   Partly answered.

2. 2. Cost base levers

   Jayant Kharote

   Question. On the cost side, you have a ~₹3,000 cr cost base. How is that split and what are the levers you can pull?

   Answer, Yashish Dahiya. Modelled illustration: ₹100 revenue split 50:50 GI/LI; GI compresses 60%, so total revenue down ~30%. With combined operating ratio pricing pass-through, price elasticity of ~1 gives 15-20% volume rebound back. On costs: indicated there may be '10-15%' revenue-to-cost synergy possible but explicitly refused to commit a number; will spend the next week-to-month working it through.

   Partly answered.

3. 3. POSP economics and international capital allocation

   Jayant Kharote

   Question. Two more questions: how does POSP work under the new IDE framework — do you have to rethink POSP? And on capital allocation, do you need to revisit the international asset decision in hindsight?

   Answer, Yashish Dahiya. On international: 'That ship has sailed long back, we have understood that was a mistake from our side.' Not revisiting in a hurry. On POSP: read regulation as-is, the business is challenged and we need to think how to manage it. Sarbvir added that from a top-line perspective POSP is challenged but bottom-line impact may move differently.

4. 4. Regulatory clarity on POSP

   Jayant Kharote

   Question. Is there regulatory clarity now on POSP, or are you waiting on something?

   Answer, Yashish Dahiya. There is clarity on what has been said so far, but this is a consultation; 'maybe there is some room for a little bit of walk back.' Described the draft as 'a little extreme compared to what the industry was expecting.'

   Partly answered.

5. 5. Life product expansion and MGA economics

   Shreya Shivani

   Question. On life side, are there thoughts around scaling up par, non-par, traditional savings and pension products? Second, can you explain the MGA model — revenue sharing dynamics if it does come up.

   Answer, Sarbvir Singh. Life NPV 'in the same neighbourhood' but not identical to today. Larger agents will not find new commission levels lucrative, so organic non-par demand will be better handled by us going forward. Credit life could re-open as a market. Non-insurance products (e.g. on Paisabazaar side) also an opportunity. MGA model: like NBFC-bank; insurer acts as wholesaler, MGA handles underwriting and claims; PB willing to put one-third to half the statutory capital.

   Partly answered.

6. 6. Non-insurance product expansion

   Shreya Shivani

   Question. Follow-up — mutual fund distribution was on Paisabazaar because it wasn't allowed under Policybazaar. Would these new product segments (credit cards, personal loans) be considered now?

   Answer, Yashish Dahiya. Confirmed absolutely — mutual funds, credit cards, personal loans are being looked at. Quoted historical fact: before Paisabazaar started, 25% of Policybazaar's revenue used to be credit cards and personal loans. Argued reciprocity: if people who sell credit cards can sell insurance, people who sell insurance should be allowed to sell credit cards.

7. 7. Industry pain points and viability

   Sachee Trivedi

   Question. You have a front-row seat into the industry. Where do you see maximum pain emerging and for which entities does the business become economically unviable — on distribution AND manufacturing side? How does the industry look next year?

   Answer, Yashish Dahiya. Quoted agent commission on fresh health policy: ~₹15,000 today, would drop to ₹3,500-₹3,750 — even at 3 policies a month the agent income falls, so some will be taken on-roll by insurers nullifying impact. Said the real industry issue is customer service and claims, not price — last price reduction drove sales up but elasticity was only ~1. 'Taking the engine out of the car and making it lighter will not make the car go faster.' Sarbvir added that 6 cr Indians buy health insurance not because of price but lack of confidence in claims; the jobs-to-be-done framework means someone has to do them at a cost.

8. 8. Ad spend, fresh business, capital allocation, Paisabazaar, renewal commissions

   Shobhit Sharma

   Question. If you rationalise advertising spend, won't that hurt organic traffic and fresh business? Second, do you expect a near-term volume push across the industry pre-implementation? Third, on capital allocation — Paisabazaar, PB Wheels, PB Care, PB Pay, Dubai haven't seen strategic turnaround despite 12 months of investment; does the ask rate for these go up? Lastly, does the regulator believe distributors earn supernormal profits given the renewal commission cuts?

   Answer, Yashish Dahiya. On ad rationalisation: 'We were spending ₹100 to make ₹100 at the margin… if suddenly instead of ₹100 I'm making ₹30, I can't spend 100 rupees to make 30 rupees.' H1 2026 hires were ~6,000 — would have been ~2,000 in new regime; going forward, vintage productivity (people past 6 months) is the offset. On Paisa/UAE: 'We are not so weak yet that we start taking irrational calls… these businesses are profitable by themselves.' Capital allocation will protect core; some capital may go toward being rewarded for risk/persistency. On renewal cuts: 'Our profits are still under 2% of total premiums that we do. If this was such a lucrative industry, we should have at least 10 more competitors.'

9. 9. Retrospective vs prospective, health vs life

   Ashwin Mehta

   Question. Health renewals are the bigger hit. If health is retrospective, can life be prospective? Will insurers agree to raise life renewal commissions on the back book?

   Answer, Yashish Dahiya. 'I can't answer that question… I don't have any clarity on whether it's retrospective or not.' Sarbvir added: too early, only 24 hours since the paper.

   Not answered directly.

10. 10. Product mix levers, POSP viability, M&A

    Dipanjan Ghosh

    Question. On manufacturers you work with — group business, PB corporate, credit life — commission ceilings differ across product segments vs core retail health. Can you lever favourable revenue from those other products sold by the same manufacturer? On POSP, how does it survive on a standalone basis given agency-broker differential? And do you see scope to acquire small brokers/agents given your lead funnel strength?

    Answer, Yashish Dahiya. On M&A: 'No. We are not in a mode of acquiring any of the small brokers or agents, because fundamentally the DNA doesn't match.' On POSP: it's a question mark and will be raised with the regulator; a broker carries higher responsibility than an agent, so paying agent more than broker/POSP is not convincing. Sarbvir added that POSP provides tech/customer management as a 'second job' which costs money and needs rewarding.

    Partly answered.

11. 11. Manufacturing optionality

    Supratim Datta

    Question. Given prior signals that you could become an insurer, does this make the manufacturing direction more imminent?

    Answer, Yashish Dahiya. 'Yes, there would be a higher probability of us having some manufacturing capability of our own, because we have to defend ourselves.' Quoted health combined operating ratio of 93% with capital economics — ₹30 capital + ₹5 interest + ₹7 = ₹12, that's 40% RoE; reinsured at 20% on 50% volume can drive 60% RoE. 'If somebody expects it to be more profitable than that, that's an unfair expectation.' Prefers to keep operating on combined operating ratio basis with partners and pass benefit to customer.

12. 12. Services monetisation vs distributor scope

    Supratim Datta

    Question. On monetising services like Garage Network — does the regulation classify any payment to the distributor as commissions?

    Answer, Yashish Dahiya. Clarified: 'This is not the distributor, my friend. These are separate companies… PB Garage, PB Wheels, PB Care+, PB Health, these are all separate companies. The distributor does not do any of these activities.'

13. 13. Protecting renewal commission book

    Nidhesh Jain

    Question. Renewal revenue is the biggest hit given the sharp cut in health commission. Is there any way to protect renewal revenue?

    Answer, Sarbvir Singh. Described it as an implicit contract with insurer partners: Policybazaar sourced business in year 1, partners expected to share economics over the lifetime. Policybazaar claims lowest port share and brings fresh, younger lives. 'We were paid a certain amount for fresh, and a certain amount we were supposed to be paid for renewal.' Yashish added: Policybazaar brings at least 50% of young lives in fresh business; industry cannot afford to lose that. Doesn't expect partners to renege.

Topic by topic, in the order it was spoken

In their words